CurifyLabs' $14M Funding Boosts Personalized Medicine in ASEAN

CurifyLabs Secures $14M to Expand Personalized Medicine in ASEAN Pharmacies and Factories \\[](https://example.com) \\[Helsinki-based health technology firm CurifyLabs has secured a $14 million Series A funding round, co-led by Sandwater and HealthCap. This significant investment will be used to expand the company's presence in the United States and enhance its supply chain infrastructure, customer support, and product development. The core of CurifyLabs' business is the Compounding System Solution (CSS), an innovative platform that combines proprietary software with GMP-manufactured excipient bases and 3D printing hardware to automate pharmacy compounding. This system ensures faster and more precise delivery of customized doses and dosage forms, outperforming traditional manual methods. Currently, the technology is deployed in pharmacies across 21 U.S. states and throughout Europe, where it compounds and dispenses thousands of doses daily. \\["Personalized medicine is one of the most important frontiers in healthcare, enabling better patient outcomes and experiencing solid growth. We are enabling more pharmacies to deliver personalized medicine in a safer and more efficient way," said Morten E. Iversen, partner at Sandwater. \\[The recent funding will also advance the CurifyLabs platform, including the newly launched PharmaPrinter Aurum, which can compound medications up to nine times faster than manual workflows. The technology is ISO 13485 certified and designed to comply with FDA 503A/503B standards for non-sterile compounding, making it well-suited for the U.S. market. Charlotta Topelius, founder and CEO of CurifyLabs, emphasized the importance of this funding in raising the bar for clinical rigor, product quality, and customer support. \\[### What This Means for ASEAN Factories \\[The expansion of CurifyLabs' technology into the U.S. and Europe sets a precedent for the potential adoption of similar systems in ASEAN countries. For factories in Thailand, Vietnam, Indonesia, and Malaysia, this could mean a significant shift towards more efficient and precise medication production. The automation and precision offered by the CSS platform can help these factories meet the growing demand for personalized medicine, ensuring higher quality and consistency in their products. Additionally, the regulatory compliance and quality control features of the system can help ASEAN manufacturers adhere to international standards, opening up new export opportunities. \\[### Automating a Manual Corner of Pharmacy \\[CurifyLabs' approach to automating pharmacy compounding is unique. Instead of developing new drugs, the company focuses on automating the process within the pharmacy itself. This not only speeds up the production of personalized medications but also reduces the risk of human error. The $14 million in funding will enable the company to scale its supply chain and U.S. presence, setting the stage for potential expansion into other markets, including ASEAN. \\[### Conclusion \\[The success of CurifyLabs' funding round highlights the growing interest in personalized medicine and the role of automation in achieving it. For ASEAN factories, this presents an opportunity to adopt advanced technologies that can improve efficiency, quality, and compliance. By investing in similar systems, ASEAN manufacturers can stay competitive in the global market and meet the increasing demand for personalized healthcare solutions. \\[Factory buyers in ASEAN should consider the potential benefits of adopting automated compounding systems like those offered by CurifyLabs. These systems can not only enhance the quality and consistency of their products but also open up new markets and opportunities for growth. As the healthcare industry continues to evolve, staying ahead of the curve with cutting-edge technology will be crucial for long-term success.](https://example.com)